25 Mar, 2019

CIRCULOGENE’s Precision Genomic Profiling Technology Featured in Three AACR 2019 Abstracts

Posters present data on utility of cfDNA for patient mutation load in NSCLC; cfRNA PD-L1 + MSI single-blood-tube testing; and innovative salvage of buccal NGS testing BIRMINGHAM, Ala.--(BUSINESS WIRE)-- CIRCULOGENE, advancing precision medicine through personalized [...]

19 Feb, 2019

CIRCULOGENE Names Anthony L. Schmidt, M.D., as Medical Director

CIRCULOGENE Names Anthony L. Schmidt, M.D., as Medical Director BIRMINGHAM, Ala. – CIRCULOGENE, advancing precision medicine through molecular genetics testing, has named Anthony L. Schmidt, M.D., F.A.C.P., as Medical Director. Dr. Schmidt will lead the [...]

13 Feb, 2019

CIRCULOGENE Molecular Diagnostics Laboratory Receives College of American Pathologists (CAP) Accreditation

 BIRMINGHAM, Ala. – CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, announced today that its molecular diagnostics laboratory has received College of American Pathologists (CAP) accreditation based on a recent on-site inspection as part [...]

4 May, 2018

CIRCULOGENE’s PD-L1 Expression Test Featured in Clinical Lab Products Magazine

In the latest feature from Clinical Lab Products magazine, experts from First Health, Banner Health and Biodesix Inc. discuss progress and challenges on the way to a blood-based assay for PD-L1. The article, "Overcoming Immune Blockade in [...]

3 May, 2018

The Evolution of In Situ Genetic Technology

This review presents a perspective of in situ genetic technology, including a summary of the methods, principles, endpoints, and applications. The class of in situ genetic techniques has been used for direct measurement of gene functions in specific cell [...]

6 Feb, 2018

Somatic Mutations in Cancer-Free Individuals: A Liquid Biopsy Connection

Somatic Mutations in Cancer-Free Individuals: A Liquid Biopsy Connection Open Acc J Oncol Med 2018. Abstract  Somatic mutations have been perceived as the causal event in the origin of the vast majority of cancers. Advanced massively [...]

12 Jan, 2018

Pre-Analytical Assessment of Circulating Cell-Free DNA Prepared by An Isolation-Free Enrichment Technology

Publication: ACTA Scientific Cancer Biology Volume 2 Issue 1 January 2018 Abstract Quantity and quality of circulating cell-free DNA (cfDNA) from plasma is highly variable, with frequent contamination of larger, genomic DNA as a consequence [...]

11 Jan, 2018

2018 Research Confirms CIRCULOGENE’s Clean Technology

Circulogene's Chief Scientific Officer, Dr. Chen-Hsiung Yeh, authored the latest research findings in ACTA Scientific Cancer Biology, Volume 2, Issue 1. This is the first paper released in 2018, which has important findings that include: Confirming, [...]

3 Jan, 2018

CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory

CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory Company expands single-blood-tube, cancer-targeted therapy and immunotherapy testing to parts of Europe, Africa, the Middle East and Commonwealth of Independent States (CIS) [...]

29 Nov, 2017

CIRCULOGENE Appoints Dr. Glen J. Weiss as Chief Medical Officer

BIRMINGHAM, Ala. ­­­– CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, has named medical oncologist and cancer researcher Glen J. Weiss, M.D., MBA, as Chief Medical Officer. Dr. Weiss will oversee and advance the [...]